NextCure, Inc. develops targeted cancer therapies as a clinical-stage biopharmaceutical company, with news centered on antibody-drug conjugate programs and related financial updates. Its principal update themes include SIM0505, a Cadherin-6-directed ADC with a topoisomerase 1 inhibitor payload, and LNCB74, a B7-H4-directed ADC.
Company announcements also cover clinical data presentations, FDA interactions such as Fast Track designation for SIM0505 in platinum-resistant ovarian cancer, collaborations with Simcere Zaiming, business updates, financial results, and participation in healthcare investor conferences.
NextCure (Nasdaq: NXTC), a clinical-stage biopharmaceutical company, will present at the BofA Securities Virtual Health Care Conference on May 13th at 9:00 am Eastern time. The event will be accessible via a live audio webcast on the company's website, with a replay available two hours post-event for 30 days. NextCure focuses on developing innovative immunomedicines for cancer and immune-related diseases using its proprietary FIND-IO™ platform.